// App-Quantinova.ai

PB0297 : The use of Obinutuzumab and Ofatumumab in the treatment of immune Thrombotic Thrombocytopenic Purpura

Researchers

Presenter

  • A. Doyle

Principal Investigators

  • M. Stubbs

  • W. Lester

  • W. Thomas

  • M. Thomas

  • C. Percy

  • N. Prasannan

  • M. Scully

Medical Centers

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University College Hospitals London NHS Foundation Trust, London, England, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Thrombotic thrombocytopenic purpura

Biomarkers

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • ofatumumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved